Skip to main content
Premium Trial:

Request an Annual Quote

Biognosys Strikes Drug Discovery, Development Deal With Kymera Therapeutics

NEW YORK — Biognosys said on Tuesday that it has signed an agreement to use its proteomics panels to help advance Kymera Therapeutics' drug-discovery and clinical trial efforts.

Kymera is developing small molecules designed to degrade specific proteins in order to treat a range of immune-inflammatory diseases and cancers.

Under the terms of their alliance, the companies will use Biognosys' recently launched TrueSignature platform to monitor and quantify protein degradation associated with Kymera drug candidates. TrueSignature enables the creation of customized panels of up to 100 proteins for pharmacodynamic readouts and clinical biomarker monitoring.

Financial and other terms of the deal were not disclosed.

"Biognosys has been a valued partner as we continue to expand our clinical pipeline across a diverse set of diseases and indications," Kymera Cofounder, President, and CEO Nello Mainolfi said in a statement. "The company's high-precision custom proteomics panels enable us to monitor and quantify protein degradation across all aspects of drug development, including preclinical and clinical programs."

In late 2021, Zurich-based Biognosys expanded an ongoing partnership with Indivumed focused on precision cancer drug discovery.

The Scan

Monkeypox Meeting

As the World Health Organization gets ready to hold another monkeypox meeting, the US distributes vaccines and increases its testing capacity.

CRISPR's Softer Side

A homologous chromosome-templated repair approach to gene editing relies on versions of the Cas9 enzyme that cut a single DNA strand.

Pickled? No Problem

Researchers come up with an approach for extracting DNA from archived museum specimens. 

Nature Papers on Long Reads for Bacterial Genomes, Zebrafish Atlas, Hypothalamic Aging in Mammals

In Nature this week: near-finished microbial genomes without polishing, zebrafish functional annotation program, and more.